Kazia Therapeutics (KZIA) Common Equity (2009 - 2025)

Kazia Therapeutics (KZIA) has 14 years of Common Equity data on file, last reported at -$5.3 million in Q2 2025.

• In Q2 2025, Common Equity rose 19.47% year-over-year to -$5.3 million; the TTM figure through Jun 2025 stood at -$5.3 million (up 19.47% YoY), while the FY2025 annual figure was -$5.3 million, up 19.47% from the prior year.
• Common Equity climbed to -$5.3 million in Q2 2025, from -$6.6 million in the prior quarter.
• Across five years, Common Equity topped out at $29.1 million in Q2 2021 and bottomed at -$6.6 million in Q2 2024.
• A 5-year average of $7.1 million and a median of $7.6 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity jumped 214.84% — and 2024, when it plunged 181.97%.
• Year by year, Common Equity stood at $29.1 million in 2021, then sank by 73.89% to $7.6 million in 2022, then sank by 54.94% to $3.4 million in 2023, then slumped by 292.51% to -$6.6 million in 2024, then increased by 19.47% to -$5.3 million in 2025.
• The last three Common Equity figures came in at -$5.3 million (Q2 2025), -$6.6 million (Q2 2024), and $3.4 million (Q4 2023), per Business Quant data.

Peer Comparison